Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026
Rhea-AI Summary
Sana Biotechnology (NASDAQ:SANA) will present clinical data on UP421, an allogeneic primary islet cell therapy using its hypoimmune platform (HIP), in a first-in-human transplant for type 1 diabetes without immunosuppression. The symposium occurs at the EASD Annual Meeting 2026 in Milan, Italy, on October 2, 2026.
Positive
- None.
Negative
- None.
News Market Reaction – SANA
In the Jul 1 session, SANA gained 2.01%, reflecting a moderate positive market reaction. Argus tracked a peak move of +7.1% during that session. Our momentum scanner triggered 32 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 27 | Investor conferences | Positive | +2.3% | June investor conference appearances with business overview and corporate update. |
| May 15 | ATM equity raise | Negative | -2.2% | Sale of common shares via ATM facility raising new capital and extending runway. |
| May 11 | Earnings & pipeline | Neutral | -8.4% | Q1 2026 financials with cash runway update and multiple pipeline program updates. |
| May 05 | Investor conference | Positive | +4.3% | BofA healthcare conference presentation with webcasted business overview and update. |
| Apr 27 | Preclinical data talk | Positive | +2.8% | ASGCT oral presentation highlighting preclinical CD19 in vivo CAR T data for SG293. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news shows mixed share reactions, with conference and data presentations often positive but financing and earnings drawing pressure.
Key Terms
allogeneic medical
islet cell therapy medical
hypoimmune platform (hip) technology medical
immunosuppression medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, July 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced a symposium presentation highlighting clinical data from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s hypoimmune platform (HIP) technology, into a patient with type 1 diabetes without any immunosuppression. The symposium will be held at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 taking place from September 28 - October 2, 2026 in Milan, Italy.
| Symposium Title: | Stem cell-derived islets in clinical trials: towards a cure for type 1 diabetes |
| Presentation Title: | Hypoimmune islets: engineering immune evasion for durable transplantation without immunosuppression |
| Presentation Date: | Friday, October 2, 2026 |
| Presentation Time: | 9:10 - 9:30 a.m. CEST |
About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision; the symposium presentation at the European Association for the Study of Diabetes Annual Meeting 2026; and the subject matter of such presentation. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as economic, market and social disruptions. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Quarterly Report on Form 10-Q dated May 11, 2026. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Investor Relations & Media:
Nicole Keith
investor.relations@sana.com
media@sana.com
